Tezacaftor (CAS 1152311-62-0): A Key Pharmaceutical for Cystic Fibrosis Management
Discover the advanced properties and applications of Tezacaftor, a vital CFTR modulator for cystic fibrosis treatment.
Get a Quote & SampleUnlocking Therapeutic Potential for Cystic Fibrosis
Tezacaftor (CAS 1152311-62-0)
Tezacaftor, identified by CAS number 1152311-62-0, is a groundbreaking pharmaceutical chemical designed to address the underlying causes of cystic fibrosis. It functions as a CFTR corrector, assisting in the proper folding and trafficking of the Cystic Fibrosis Transmembrane Conductance Regulator protein to the cell surface. This mechanism is crucial for restoring chloride channel activity, thereby alleviating the symptoms associated with this genetic disorder. As a key component in combination therapies like Symdeko and Trikafta, Tezacaftor represents a significant advancement in treating patients with specific CFTR gene mutations.
- Discover the efficacy of Tezacaftor pharmaceutical chemical in improving CFTR protein function for cystic fibrosis patients.
- Explore the CAS 1152311-62-0 CFTR corrector's role in advanced cystic fibrosis treatment protocols.
- Understand the drug for CFTR gene mutation, highlighting Tezacaftor's impact on patient health outcomes.
- Learn about the Tezacaftor combination therapy, including its applications in Symdeko and Trikafta formulations.
Key Advantages and Properties of Tezacaftor
Enhanced CFTR Protein Function
Tezacaftor, as a potent CFTR modulator, significantly enhances the function of the CFTR protein, offering a targeted approach to managing cystic fibrosis. This drug for CFTR gene mutation offers hope for patients with specific genetic profiles.
High Purity and Quality Standards
With an assay typically exceeding 99%, Tezacaftor (CAS 1152311-62-0) meets stringent pharmaceutical standards, ensuring its safety and efficacy for therapeutic use and pharmaceutical research & development.
Proven in Combination Therapies
The utility of Tezacaftor combination therapy is well-established in leading treatments like Symdeko and Trikafta, demonstrating its critical role in improving patient outcomes and quality of life.
Key Applications
Cystic Fibrosis Treatment
Tezacaftor is a cornerstone in the treatment of cystic fibrosis, directly addressing the malfunctioning CFTR protein characteristic of the disease.
CFTR Protein Correction
Its primary application involves correcting the misfolding and trafficking defects of the F508del-mutated CFTR protein, thereby restoring some normal function.
Pharmaceutical Research & Development
As a well-characterized API, Tezacaftor serves as a vital compound for ongoing pharmaceutical research and the development of next-generation CF therapies.
Drug Intermediate Synthesis
The high-quality production of Tezacaftor supports its use as an intermediate in the synthesis of complex pharmaceutical compounds for genetic disorders.